Les serves as Vice President of Clinical Development of Erasca, bringing more than 20 years of experience as a scientifically-driven oncology drug developer in early phase clinical development and translational medicine. Les joined Erasca from Neon Therapeutics, where he led the clinical development of the personalized neoantigen vaccine program. He also led the clinical development of their shared neoantigen vaccine program resulting in the recent filing of the IND for this program. Prior to this, he served as the Program Team Leader of IPI-549, a PI3K-gamma inhibitor, at Infinity Pharmaceuticals. At Infinity, Les was responsible for the strategic and operational aspects of the molecule including the first-in-human study, IND filing and development of the overall clinical strategy. He began his career at Eli Lilly and Company in their early phase Oncology drug development group where he was the clinical lead on multiple programs, responsible for Phase I and II development. Les worked closely with the pre-clinical development teams to optimize the characteristics of the drug development candidates with a focus on clinically relevant biomarkers.
He earned his Ph.D. in Medical Biophysics from the University of Toronto.
Dr. Glassy graduated from the University of San Francisco in 1974 with a B.S. in Biology and Chemistry. He then attended University of California, Riverside and received his Ph.D. in biochemistry in 1978. He did his post-doctoral studies in molecular immunology at the Scripps Research Institute in La Jolla. Dr. Glassy joined the faculty of the Department of Medicine and Cancer Center at UCSD in 1980 and is currently in the Translational Neuro-Oncology Laboratory at the UCSD Moores Cancer Center. In addition to UCSD, Dr. Glassy has held several upper management positions in commercial biotechnology. He has prepared and directed several FDA approved clinical trials involving human monoclonal antibodies to cancer. Dr. Glassy has over 175 publications in the scientific and medical literature, is the inventor of several issued patents in the human antibody field, is the Editor-in-Chief of the journal, HUMAN ANTIBODIES, and the Program Chairman of the meeting series, “The International Conference on Human Antibodies and Hybridomas”. Glassy is the inventor of pritumumab, the first human antibody used to treat a cancer patient and is the recipient of the 2003 Arthur Furst Award (citation: “Outstanding research advancing science for the betterment of humanity”). He is also the author of the books, “The Biology of Science Fiction Cinema”, “Movie Monsters in Scale”, and “Biology Run Amok!”.
Co-founder and Head of Software at Simulytica, defining the strategy and architecture of digital transformation technologies and software systems. A computer scientist with extensive experience in AI, ML, VR, and simulation systems technologies. He is the architect of numerous large-scale software systems within the oil & gas and nuclear industries, and the developer of world-renowned software in the interactive games industry including Tomb Raider.
Co-founder and Head of Engineering at Simulytica, responsible for the development of engineering functionality across the Simulytica product line and the specification of future software products and their alignment to industry needs. With a proven track record and extensive experience in the design, analysis and troubleshooting of gas compression systems.
Peter brings over thirty years’ experience in industrial control systems design and operation to his current role as the Global Solutions Architect for asset performance.
